ESPR - Esperion - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

782.7M

Cash

226.6M

Avg Qtr Burn

-6.826M

Short % of Float

24.01%

Insider Ownership

0.52%

Institutional Own.

69.12%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Nexletol (bempedoic acid) Details Heterozygous familial hypercholesterolemia, Atherosclerotic cardiovascular disease , Hypercholesterolemia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nexlizet (bempedoic acid and ezetimibe) Details Hypercholesterolemia, Atherosclerotic cardiovascular disease , Heterozygous familial hypercholesterolemia, Cardiovascular risk reduction	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.